immuno oncology frontiers world miami


Scott Bornheimer

Dr Scott Bornheimer

Applied research manager, BD Biosciences
Dr. Bornheimer is Manager of Applied Research and Scientific Affairs at BD Biosciences, where he works on the development and application of new technologies for single cell research, patient diagnostics, and cell therapy manufacturing. He previously led the R&D effort to develop and commercialize an extremely easy-to-use IVD cytometry system for CD4, %CD4, and Hb measurements for HIV/AIDS patients in resource limited settings (BD FACSPresto).  He joined BD to apply science and technology to directly impact patient lives, entering through the Technology Leadership Development Program.  Dr. Bornheimer received a PhD from UC San Diego in Chemistry and Biochemistry, under joint mentorship in the departments of Cellular and Molecular Medicine and Bioengineering, where he investigated heterotrimeric G-protein signaling through computational modeling, development of new biosensors, and live cell fluorescent imaging approaches.  
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy